Effects of growth hormone treatment for short stature on calcium homeostasis, bone mineralisation, and body composition

Horm Res. 1994;41(1):16-20. doi: 10.1159/000183871.

Abstract

We investigated the effect of growth hormone (GH) treatment on mineral and vitamin D homeostasis, bone mineralisation, and body composition in short-statured children without GH deficiency (GHD). 11 children received GH (0.50 +/- 0.08 IU/kg/week) for 24 weeks. 1,25-Dihydroxyvitamin D3 levels (mean +/- SD in pmol/l) rose from a baseline of 73.7 +/- 39.2 to 114.0 +/- 32.7 at 8 weeks (p < 0.05) and 111.9 +/- 39.7 at 24 weeks (p < 0.01). Body composition evaluation using dual-energy X-ray absorptiometry revealed increased lean tissue mass and a reduction in fat tissue. As a percentage of total body mass, fat decreased from 19.0 +/- 11.8% at baseline to 17.3 +/- 11.5% at 8 weeks (p < 0.005) and 16.8 +/- 11.5% at 24 weeks (p < 0.05). L2-L4 bone mineral density was 0.637 +/- 0.155 g/cm2 at baseline and 0.666 +/- 0.160 g/cm2 at 24 weeks (NS). We conclude that recombinant human GH treatment of short children without GHD has significant effects on vitamin D homeostasis and body composition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Body Composition / drug effects*
  • Calcification, Physiologic / drug effects*
  • Calcitriol / blood
  • Calcium / metabolism*
  • Child
  • Female
  • Growth Disorders / drug therapy*
  • Growth Hormone / adverse effects
  • Growth Hormone / pharmacology*
  • Growth Hormone / therapeutic use
  • Homeostasis / drug effects*
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Prospective Studies
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use

Substances

  • Recombinant Proteins
  • Insulin-Like Growth Factor I
  • Growth Hormone
  • Calcitriol
  • Calcium